ENTRY       D03505                      Drug
NAME        Cinacalcet hydrochloride (JAN/USAN);
            Sensipar (TN);
            Mimpara (TN)
PRODUCT     SENSIPAR (A-S Medication Solutions)
            SENSIPAR (Amgen)
  GENERIC   CINACALCET (ACI Healthcare USA)
            CINACALCET (Accord Healthcare)
            CINACALCET (American Health Packaging)
            CINACALCET (Ascend Laboratories)
            CINACALCET (Aurobindo Pharma Limited)
            CINACALCET (AvKARE)
            CINACALCET (AvPAK)
            CINACALCET (Bryant Ranch Prepack)
            CINACALCET (Bryant Ranch Prepack)
            CINACALCET (Bryant Ranch Prepack)
            CINACALCET (Bryant Ranch Prepack)
            CINACALCET (Bryant Ranch Prepack)
            CINACALCET (Bryant Ranch Prepack)
            CINACALCET (Camber Pharmaceuticals)
            CINACALCET (Cipla USA)
            CINACALCET (Dr. Reddys Laboratories)
            CINACALCET (EXELAN PHARMACEUTICALS)
            CINACALCET (Golden State Medical Supply)
            CINACALCET (Major Pharmaceuticals)
            CINACALCET (Strides Pharma Science Limited)
            CINACALCET (Strides Pharma)
            CINACALCET (Sun Pharmaceutical Industries)
            CINACALCET (XLCare Pharmaceuticals)
            CINACALCET HYDROCHLORIDE (Amneal Pharmaceuticals LLC)
            CINACALCET HYDROCHLORIDE (Slate Run Pharmaceuticals)
FORMULA     C22H22F3N. HCl
EXACT_MASS  393.1471
MOL_WEIGHT  393.8729
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01645  CYP2D6 inhibitor
REMARK      Therapeutic category: 3999
            ATC code: H05BX01
            Chemical structure group: DG00513
            Product (DG00513): D03505<JP/US>
EFFICACY    Antihypercalcemia, Antihyperparathyroidism, Calcium sensing receptor allosteric modulator
  DISEASE   Secondary hyperparathyroidism [DS:H01669]
            Parathyroid carcinoma [DS:H01558]
            Primary Hyperparathyroidism [DS:H00246]
COMMENT     Treatment of hyperparathyroidism and related disorders, such as hypercalcemia (reduction of PTH secretion through modulation of calcium ion receptors on parathyroid cells)
TARGET      CASR [HSA:846] [KO:K04612]
  PATHWAY   hsa04621(846)  NOD-like receptor signaling pathway
            hsa04928(846)  Parathyroid hormone synthesis, secretion and action
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION CYP inhibition: CYP2D6 [HSA:1565]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
              H05 CALCIUM HOMEOSTASIS
               H05B ANTI-PARATHYROID AGENTS
                H05BX Other anti-parathyroid agents
                 H05BX01 Cinacalcet
                  D03505  Cinacalcet hydrochloride (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Metabolic Bone Disease Agents
              Calcium-sensing Receptor Agonist
               Cinacalcet
                D03505  Cinacalcet hydrochloride (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D03505  Cinacalcet hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00513  Cinacalcet
                 D03505  Cinacalcet hydrochloride
             Metabolizing enzyme inhibitor
              DG01645  CYP2D6 inhibitor
               DG00513  Cinacalcet
                D03505  Cinacalcet hydrochloride
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Metabotropic glutamate receptor family
               Calcium-sensing
                CASR
                 D03505  Cinacalcet hydrochloride (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03505
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03505
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03505
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03505
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D03505
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00513  Cinacalcet
             Metabolizing enzyme inhibitor
              DG01645  CYP2D6 inhibitor
               DG00513  Cinacalcet
DBLINKS     CAS: 364782-34-3
            PubChem: 17397639
            ChEBI: 48391
            LigandBox: D03505
            NIKKAJI: J2.128.387H
ATOM        27
            1   C8x C    14.3657  -13.4461
            2   C8y C    14.3657  -14.8469
            3   C8y C    15.5788  -15.5473
            4   C8y C    16.7920  -14.8469
            5   C8x C    16.7920  -13.4461
            6   C8x C    15.5788  -12.7457
            7   C8x C    13.1526  -15.5473
            8   C8x C    13.1526  -16.9481
            9   C8x C    14.3657  -17.6485
            10  C8x C    15.5788  -16.9481
            11  C1c C    18.0302  -15.5473
            12  N1b N    19.2433  -14.8469
            13  C1b C    20.4564  -15.5473
            14  C1b C    21.6695  -14.8469
            15  C1b C    22.8828  -15.5473
            16  C1a C    18.0365  -16.9620
            17  C8y C    24.0711  -14.8611
            18  C8x C    25.2666  -15.5514
            19  C8y C    26.4808  -14.8505
            20  C8x C    26.4809  -13.4486
            21  C8x C    25.2853  -12.7582
            22  C8x C    24.0711  -13.4592
            23  C1d C    27.7137  -15.5624
            24  X   F    28.9108  -16.2538
            25  X   F    28.4104  -14.3558
            26  X   F    27.0085  -16.7838
            27  X   Cl   32.4800  -15.4700
BOND        28
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     2   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    3  10 1
            12    4  11 1
            13   11  12 1
            14   12  13 1
            15   13  14 1
            16   14  15 1
            17   11  16 1 #Down
            18   15  17 1
            19   17  18 2
            20   18  19 1
            21   19  20 2
            22   20  21 1
            23   21  22 2
            24   17  22 1
            25   19  23 1
            26   23  24 1
            27   23  25 1
            28   23  26 1
///
